The present disclosure provides for methods, devices, and compositions for controlling factors involved in the healing of lesions. The methods, devices, and composition include a first therapeutic agent which includes an amount of MCP-1 and/or osteopontin effective to promote recruitment of macrophages to the lesion site. In additional embodiments, there is further provided a second therapeutic agent which includes an inhibitor of at least one of IL-17A, CXCL1, or IL-6 to promote polarization of an amount of the macrophages to M2 phenotype macrophages at the lesion site.

The present invention provides a CCL20 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of psoriasis and psoriatic arthritis.

The present disclosure relates to systems and methods for immune therapy. For example, a method can be used to enhance proliferation of chimeric antigen receptor (CAR) T cells in a patient, The method comprises administering to the patient an effective amount of a pharmaceutical composition comprising lymphocyte activation agents and one or more recombinant viral particles comprising a polynucleotide encoding a CAR, wherein the proliferation of CAR T cells in the patient is greater as compared to a patient administered with the one or more recombinant viral particles but without the lymphocyte activation agents.

This disclosure relates to compositions and methods for recruiting brown adipocytes in vitro and in vivo from brown adipocyte progenitor cells found in human skeletal muscle. Methods for treating metabolic disease are also provided. Additionally, methods for treating hypothermia are provided. In some embodiments, the brown adipocyte recruiter is a human protein or peptide. In other embodiments the brown adipocyte recruiter may be a non-human protein or peptide. In still other embodiments, the brown adipocyte recruiter is a small molecule or natural product.

The present invention relates to a biomaterial comprising adipose-derived stem cells (ASCs), a ceramic material and an extracellular matrix. In particular, the biomaterial according the present invention secretes osteoprotegerin (OPG), and comprises insulin-like growth factor (IGF1) and stromal cell-derived factor 1-alpha (SDF-1α). The present invention also relates to methods for producing the biomaterial and uses thereof.

The present invention relates to a biomaterial comprising adipose-derived stem cells (ASCs), a ceramic material and an extracellular matrix. In particular, the biomaterial according the present invention secretes osteoprotegerin (OPG), and comprises insulin-like growth factor (IGF1) and stromal cell-derived factor 1-alpha (SDF-1α). The present invention also relates to methods for producing the biomaterial and uses thereof.

Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.

The present application provides a method of making a particle comprising (i) obtaining a first solution comprising a negatively charged polysaccharide; (ii) obtaining a second solution comprising a positively charged polysaccharide; and (iii) mixing the first solution and the second solution to obtain a suspension comprising the particle. The present application also provides a method of making a therapeutic particle, comprising: (i) obtaining a solution comprising a therapeutic protein; (ii) obtaining a first suspension comprising the particle comprising a negatively charged polysaccharide and a positively charged polysaccharide, and (iii) mixing the solution of the therapeutic protein and the first suspension to obtain a second suspension comprising the therapeutic particle. The present application also provides particles (e.g., therapeutic particles) prepared by any one of the disclosed methods, as well as the compositions comprising such particles, and methods of treating a disease or condition using such particles and compositions.

A technology regarding the production, formulation and use of conditioned media and the factors included therein is disclosed. The conditioned media may be inoculated with animal cells, plant cells and any combination thereof. The inoculations may occur simultaneous or at different times. Cells retrieved from different areas of the animal and/or the plant may also be cultured together to form conditioned media and associated growth factors.

The present invention relates to methods and pharmaceutical composition for treating inflammatory diseases. Inflammation is a defence response to tissue damage or infections that requires tight regulation to prevent impaired healing and to avoid excessive damage and/or autoimmunity. Myeloid cells, including macrophages play a key role in tissue repair and undergo major functional changes during the healing processes, switching from an inflammatory state to a pro-repair phenotype. The inventors have found that TAFA4, a chemokine-like protein, has anti-inflammatory and pro-repair properties. This molecule regulates the phenotype of man monocytes and macrophages by promoting their anti-inflammatory and pro-repair functions. TAFA4 increases macrophage their phagocytic capacities and their production of the anti-inflammatory cytokine IL-10. By contrast, TAFA4 down-regulates the production of the pro-inflammatory cytokines IL-6, IL-113, and TNF-α by human macrophages. Importantly, the inventors have also found that a treatment with TAFA4 has anti-inflammatory effects in vivo and protects mice from LPS-induced endotoxic shock. This protective effect is associated with a reduction in inflammatory cytokine levels and an increase in EL-10 production. Finally, they found that TAFA4 can also exert its anti-inflammatory properties on peripheral blood mononuclear cells from COVID-19 patients, independently of the disease severity. Thus, the present invention relates to a TAFA4 polypeptide or a nucleic acid molecule encoding thereof for use in the treatment of inflammatory diseases.